Hikma Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Hikma Pharmaceuticals
Public company (LSEHIK)
Industry Pharmaceutical
Founded 1978
Headquarters London, UK
Key people
Samih Darwazah Chairman
Said Darwazah CEO
Products Amoclan
Revenue US$1,365 million (2013)[1]
US$413 million (2013)[1]
US$216 million (2013)[1]
Number of employees
circa 6,000 (2012)
Slogan Improving people's quality of life globally
Website www.hikma.com

Hikma Pharmaceuticals is a multinational pharmaceutical company based in London, that manufactures branded and non-branded generic and in-licensed pharmaceutical products. It was first listed on the London Stock Exchange in 2005 is now the fourth listed pharmaceutical company on the FTSE 250 Index.[2] In 2013, Hikma delivered 23% group revenue growth [3] and is the largest regional pharmaceutical company in the MENA region.[4] It was founded in Jordan in 1978 by Samih Darwazah.


The Company was founded by Samih Darwazah in 1978 in Amman in Jordan.[5] In August 1996 it became the first Arab company to export pharmaceutical products to the United States.[6] It was first listed on the London Stock Exchange in 2005.[5] Recent acquisitions include Instituto Biochimico Pavese Pharma in Italy in 2005[7] and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006.[5] In 2007 the Company went on to buy APM in Jordan,[8] Alkan Pharma in Egypt,APM and Al Jazeera Pharma in Saudi Arabia[8] Thymoorgan in Germany[5] and Ribosepharm in Germany.[5] It also acquired Multi-Source Injectables in the USA in October 2010.[9] In May 2011 Hikma Pharmaceuticals PLC complete the acquisition of Baxter Healthcare Corporation's US generic injectables business (Multi-Source Injectables or MSI).[10][11]

In October 2011, Hikma Pharmaceuticals entered the Moroccan market through the acquisition of Promopharm, the ninth largest pharmaceutical manufacturer in Morocco.[12] Hikma also inaugurated the Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria in 2011. The Algerian pharmaceutical company is Hikma’s second venture in Algeria after Hikma Pharma Algeria.[13]

In 2011 the company won the ICSA / Hermes Transparency in Governance Award for the best audit disclosure for a FTSE 250 company.[14]

Hikma expanded its existing presence in the Egyptian market through the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries (EPCI) in 2012.[15] In September 2013, Hikma announced expansion into Sub-Saharan Africa with a 50:50 joint venture agreement with MIDROC Pharmaceuticals Limited, to enter the Ethiopian pharmaceutical market [16]

On May 28, 2014, Hikma Pharmaceuticals agreed to acquire assets from the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million, boosting its presence in the injected medicine market.[17]


Hikma Pharmaceutical’s operations span over 50 countries with 26 manufacturing plants in 11 countries, and 7 R&D centers.[18] The Company's production facilities are located in the following countries:

Business Segments[edit]


Hikma’s branded business segment comprises the development and sales of branded generics and in-licensed patented products in the MENA region. Hikma has 499 products in 1,256 dosage strengths. Top products include Amoclan, Blopress, Omnicef, Prograf and Suprax.[19]


Hikma sells specialized injectable products in the US, Europe and MENA including argatroban, fentanyl, phenylephrine, robaxin and iron gluconate. The company sells 200 products in 379 dosage forms and strengths.[20]


Hikma’s oral generic products are sold in the US and include such products as amoxicillin, cephalexin, doxycycline, methocarbamol and prednisone.[18]

See also[edit]


  1. ^ a b c Preliminary Results 2013
  2. ^ http://www.hikma.com/en/about-hikma/~/media/Files/H/Hikma/Attachments/pdf/hikma-factsheet-2014.pdf
  3. ^ Hikma Annual Report 2013 page 34 http://www.hikma.com/~/media/Files/H/Hikma/Attachments/pdf/reports/financial-reports/annual-report-2013.pdf
  4. ^ Investors Hikma Pharmaceuticals PLC http://www.hikma.com/en/investors/hikma-at-a-glance.aspx
  5. ^ a b c d e Hikma History
  6. ^ Economy – Sectoral Analysis
  7. ^ Hikma Annual Report 2006 Page 62
  8. ^ a b Hikma Annual Report 2007 Page 15
  9. ^ Hikma Pharma to buy Multi-Source Injectables business of Baxter Healthcare
  10. ^ "Hikma Pharmaceuticals Plc Completes Acquisition of Baxter Healthcare Corporation's Multi-Source Injectables Business". Reuters. Retrieved 3 May 2011. 
  11. ^ "History". Hikma Pharmaceuticals PLC. 
  12. ^ http://www.prnewswire.com/news-releases/hikma-enters-the-moroccan-market-through-the-acquisition-of-639-of-promopharm-and-will-launch-a-mandatory-tender-offer-for-the-remaining-361-130992148.html
  13. ^ Hikma Pharmaceuticals Inaugurates Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria http://www.zawya.com/story/ZAWYA20111018104628/
  14. ^ Hikma Receives Transparency in Governance Award 2011
  15. ^ http://www.pmlive.com/pharma_news/hikma_expands_in_egypt_with_epci_acquisition_458329
  16. ^ Hikma Annual Report 2013 page 23 http://www.hikma.com/~/media/Files/H/Hikma/Attachments/pdf/reports/financial-reports/annual-report-2013.pdf
  17. ^ http://www.reuters.com/article/2014/05/28/hikma-pharma-boehringer-idUSL6N0OE2ZU20140528
  18. ^ a b Hikma Annual Report 2013 page 10 http://www.hikma.com/~/media/Files/H/Hikma/Attachments/pdf/reports/financial-reports/annual-report-2013.pdf
  19. ^ Hikma Annual Report 2013 page 11 http://www.hikma.com/~/media/Files/H/Hikma/Attachments/pdf/reports/financial-reports/annual-report-2013.pdf
  20. ^ Hikma Factsheet 2014 http://www.hikma.com/en/about-hikma/~/media/Files/H/Hikma/Attachments/pdf/hikma-factsheet-2014.pdf

External links[edit]